Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biodistribution of Ga-68 Pentixafor in Neuroendocrine Tumors
NCT03335670Phase 1Active, not recruiting
- Start
- Nov 2017
- Primary completion
- Dec 2029
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pentixafor in neuroendocrine tumors (NETs). Primary endpoints: Biodistribution (pharmacokinetic parameters) of [68Ga]Pentixafor at 1 month and Repeatability of [68Ga]Pentixafor uptake at 1 month. Started Nov 2017; status: active, not recruiting.
02
Drugs
pentixafor
03
Conditions
neuroendocrine tumors (NETs)
Beyond the preview
Go deeper on NCT03335670.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03335670.